Cindy Rose, Microsoft's chief operating officer for global enterprise sales, is leaving the tech behemoth to become CEO ...

Absci Corporation (NASDAQ:ABSI) is a Washington-headquartered data-first generative AI drug creation company that perfectly ...

Absci Corporation. Entered into partnership with Almirall to rapidly develop novel treatments for dermatological diseases, for up to $664M in deal value, plus royalties ...

Absci becomes clinical stage company with ABS-101, first AI-designed biologic for IBD, beginning Phase 1 trial . Preclinical data for ABS-101 demonstrates high potency and potential for quarterly ...

Absci moved close to 25% higher on the 11 th of April, driven by an FDA announcement that animal testing will be phased out, starting with monoclonal antibodies.A greater focus will be placed on ...

Absci Corporation stock has dropped since January, driven by weak earnings and broader biotech sector pressures. Despite weak financials, Absci's internal pipeline, including ABS-101 and ABS-201 ...

Wednesday, Absci Corp. (NASDAQ:ABSI) shares, currently trading at $3.22, received a positive outlook from Needham as the firm began coverage with a Buy rating and set a price target of $9.00. The ...

People in Business Absci recently announced the appointment of veteran biopharmaceutical executive Mary Szela to its board of directors. With decades of research and development and commercial lea ...

Absci shares dipped 9.4% to $2.79 in the pre-market trading session. Here are some other stocks moving lower in pre-market trading. Regencell Bioscience Holdings Limited RGC shares dipped 16.1% to ...

Absci Corporation (NASDAQ:ABSI) is on track to select a development candidate for this program by the end of 2024 and plans to present a preclinical data package at its upcoming R&D Day.

About Absci Corp. Absci Corp. is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. It partne ...

Absci becomes clinical stage company with ABS-101, first AI-designed biologic for IBD, beginning Phase 1 trial . Preclinical data for ABS-101 demonstrates high potency and potential for quarterly ...